Supernus Pharma (SUPN) Misses Q4 EPS by 6c

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.27, $0.06 worse than the analyst estimate of $0.33. Revenue for the quarter came in at $174.16 million versus the consensus estimate of $150.24 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Waller: Recent Increases In Core Inflation Are Quite Broad
• PBF Energy (PBF) spreader of August 50 calls, August 55 calls and August 60 calls, share price up 8.1%
• Permian Resources (PR) call put ratio 1 call to 10 puts with a focus on July 15 and 30 puts